Introduction to the 2007 event

ACI’s Biomarkers in Drug Development Conference will address the latest applications of biomarkers within drug
discovery and development, with a key focus on integrating biomarkers earlier in clinical development, and maximising
their use as part of a personalised approach to treatment.

The programme will focus on key topics Among the speakers:

including:
• Biomarkers in early safety and toxicity assessment
• Biomarkers as validation tools – determining
validation parameters
• Challenges in development and implementation of
biomarkers
• Integrating biomarkers earlier – using markers in
early clinical development
• Translational biomarkers – bridging the gap
• Biomarkers as in vitro diagnostics
• Dr. Andrew Lockhart, CPDM-Neurology
Biomarker Group, GlaxoSmithKline
• Dr. Ann Kapoun, Associate Director, Biomarker
R&D, Clinical Pharmacology & Experimental
Medicine, ALZA
• Dr. Eric Blomme, Project Leader, Cell and
Molecular Toxicology, Abbott Laboratories
• Dr. Brian Swanson, US Head of Biomarkers,
Clinical and Experimental Pharmacology, Sanofi-
Aventis
• Dr. Yixin Wang, Group Director, Discovery
Research and Pharmaceutical Biomarker Support,
Veridex and Ortho-Clinical Diagnostics, Johnson &
Johnson

Our expert panel of speakers comprises leading executives and senior researchers from pharmaceutical and
biotechnology companies. Through case study-driven presentations, our speakers will provide an insight into
cutting-edge applications and developments in the use of biomarkers from discovery through to clinical
diagnostics, tackling issues from validation to safety and toxicity.

Who will attend?

Attendees will be drawn from pharmaceutical and biotechnology companies and include VPs, Directors and Managers of:
Biomarkers, Translational/Experimental Medicine, Clinical Research/Development, Pharmacology, Toxicology and Safety
Assessment, Clinical PK/PD, Discovery Medicine, Molecular Medicine/Diagnostics

How to attend?

We strictly limit the number of participants at the conference. That means that 80 to 100 peers from the global
pharmaceutical and biotechnology industry will be attending the event to learn from the educational elements and with
plenty of time to network with this targeted group.

We simply advised a quick registration to make sure to not miss out on the opportunity. To register or to get additional
information please contact Melanie Mulazzi of ACI on +44 207 368 1654 or mmulazzi@acius.net.

About ACI

ACI, a UK owned company, have been running successful conferences for the last 8 years in the USA. Headquartered in
Chicago with offices all around the States, they run forums in varied fields and are market leaders in Healthcare business
conferences. Opening their European head office at the end of 2005, they have expanded rapidly and are launching a
series of events covering emerging markets, the maritime industry and now the pharmaceutical industry.
* Please note that speakers and topics are liable to change *

London • Chicago • San Diego • Atlanta • Oxford

Active Communications Europe Ltd, 58-60 Kensington Church Street London, W8 4DB, United Kingdom
Tel: 0 (+44) 20 7368 1654 • Fax: 0 (+44) 20 7368 3365 • www.acius.net • Reg. in UK 5620385